Crowley Wealth Management Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crowley Wealth Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 50 shares of the biopharmaceutical company’s stock, valued at approximately $36,000.

A number of other large investors have also recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $34,468,000. Umpqua Bank grew its holdings in Regeneron Pharmaceuticals by 7.6% during the 4th quarter. Umpqua Bank now owns 1,534 shares of the biopharmaceutical company’s stock worth $1,060,000 after acquiring an additional 108 shares during the period. Forefront Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $2,206,000. Mizuho Securities USA LLC grew its holdings in Regeneron Pharmaceuticals by 45.0% during the 4th quarter. Mizuho Securities USA LLC now owns 9,977 shares of the biopharmaceutical company’s stock worth $7,107,000 after acquiring an additional 3,096 shares during the period. Finally, Quantbot Technologies LP grew its holdings in Regeneron Pharmaceuticals by 266.7% during the 4th quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company’s stock worth $376,000 after acquiring an additional 384 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $658.48 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company’s 50 day moving average price is $689.43 and its two-hundred day moving average price is $813.15. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $71.99 billion, a P/E ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.